1. Medtech Insight
  2. >>Policy & Regulation

Senators To Trump Administration: 'Way Too Late' To Change US FDA Budget Structure Now

 
• By Sue Darcey

Senate HELP Committee leaders Lamar Alexander, R-Tenn., and Patty Murray, D-Wash., said it's "way too late" for Congress to alter the budgetary balance between device and drug industry US FDA user-fee contributions and congressional appropriations for the upcoming 2018-2022 user-fee cycle in tersely worded statements to HHS Secretary Tom Price May 16.

Both Chairman Lamar Alexander, R-Tenn., and Ranking Member Patty Murray, D-Wash., of the Senate Health, Education, Labor, and Pensions Committee flatly turned down HHS Secretary Tom Price's May 15 request to "recalibrate how the FDA finances its medical product review work," by making the device and drug industry foot the bill for 100% of the agency's premarket medical product reviews.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Policy & Regulation

Precision Neuroscience’s FDA Clearance For Core Component Of Brain Implant Expected to Accelerate R&D

 
• By Marion Webb

Precision’s recent FDA clearance for a core part of its next-generation wireless brain-computer interface system opens the pathway to a safer, more humane BCI for researchers to use compared to higher-risk intracortical arrays, according to BCI expert Naveen Rao.

Trump’s Preliminary 2026 HHS Budget Plan Protects US FDA User Fee Collection

 
• By Cathy Kelly

The preliminary White House 2026 budget plan cuts agency funding, but not so sharply that user fees are excluded from collection.

Abbott, J&J Reaffirm 2025 Profit Guidance Despite Growing Tariff Uncertainties

 
• By Marion Webb

Abbott and J&J reassured investors they will maintain their 2025 profit forecasts. Abbott projects $5.05 to $5.25 per share and plans a new $500m investment in manufacturing and R&D sites. J&J anticipates $400m in tariff-related costs but committed $55bn in US investment over four years.